PCI Biotech: Invitation to fourth quarter 2020 results presentation
Oslo, Norway, 18 February 2021 - PCI Biotech’s (OSE: PCIB) fourth quarter and preliminary full year 2020 interim report will be released on 24 February 2021 at 07.00 CET. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com.
A results presentation (in English) will be held through a live webcast at 08.30 CET the same day. The webcast can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation. It will be possible to post written questions through the webcast console or through a teleconference facilitated for investors intending to ask questions verbally during the Q&A session.
For further information, please contact:
Ronny Skuggedal, CFO
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Recording of the Fourth Quarter 2020 Investor Conference Webinar2.3.2021 19:05:00 CET | Press release
On March 2, 2021 JSC Olainfarm organized its Investor Conference Online Webinar. During the webinar Chairperson of Management Board Jeroen Weites and member of the management board Zane Kotāne analyzed the financial results of fourth quarter and 12 months 2020 and informed about other recent activities within the company. The recorded webinar is available online: https://bit.ly/3kBxkw4; and the presentation, demonstrated during the webinar, is available in the attachment. Methodology for alternative performance indicators is disclosed in Annual report for 2020 (page 15). Olainfarm thanks all participants, who joined the webinar, and encourages everybody to follow company’s announcements to get information on the next webinar! JSC Olainfarm, a part of Olainfarm Group, is one of the leading pharmaceutical companies in the Baltic States offering high quality medicine and chemical pharmaceutical products. The business strategy “FORWARD” highlights the company’s main vision – to become one
Feedzai recognized in NowTech: Enterprise Fraud Management, Q1 2021 Report2.3.2021 17:46:42 CET | Press release
SAN MATEO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Feedzai, the world’s leading cloud-based risk management platform announced today that it has been recognized in Forrester’s NowTech: Enterprise Fraud Management, Q1 2021 report. The report provides an overview of 37 Enterprise Fraud Management (EFM) providers. The report is designed to help security and risk professionals understand the value they can expect from an EFM provider, while also providing guidance on selecting vendors based on their respective expertise. In addition, the report addresses critical elements in EFM solutions that reduce fraud, minimize customer friction, and provide explainable fraud models - an increasingly important element as Responsible AI discussions take place from a regulatory perspective. “The days of closed risk scoring models for fraud management are over,” writes Andras Cser, Vice President, and Principal Analyst - Security and Risk Management at Forrester Research in the report:“EFM solutions h
Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy2.3.2021 17:02:24 CET | Press release
STOCKHOLM, SWEDEN – March 2, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign has decided to carry out a fully guaranteed rights issue of SEK 240 million in combination with overallotment options of up to approximately SEK 30 million – a total of approximately SEK 270 million. The purpose of the financing is, among other things, to accelerate the company's development through the new strategy program ASCENT25. The guarantors of the rights issue include several of the company's previous major shareholders, including Karolinska Development, SEB Venture Capital and Fouriertransform. In connection with the rights issue, OssDsign presents a new corporate strategy with the purpose of realizing its potential and accelerating the development towards a positive cash flow by 2025. The great interest in the issue reflects confidence in OssDsign's capacity to advance to a new level. The new strategy, ASCENT25, aims to accelerate the compa
Karolinska Developments portföljbolag OssDsign genomför en fullt garanterad företrädesemission och lanserar ny bolagsstrategi2.3.2021 17:02:24 CET | Pressemelding
STOCKHOLM, SVERIGE 2 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen i portföljbolaget OssDsign har beslutat att genomföra en fullt garanterad företrädesemission om SEK 240 miljoner i kombination med övertilldelningsoptioner om upp till cirka SEK 30 miljoner – totalt cirka SEK 270 miljoner. Syftet med finansieringen är bland annat att acclerera bolagets utveckling genom det nya strategiprogrammet ASCENT25. Företrädesemissionens garanter inkluderar flera av bolagets tidigare storägare, bland annat Karolinska Development, SEB Venture Capital och Fouriertransform. I samband med emissionsbeslutet presenterar OssDsign en ny bolagsstrategi vars syfte är att realisera dess potential och acclerera utvecklingen mot ett positivt kassaflöde senast 2025. Den stora intresset för emissionen speglar förtroendet för OssDsigns kapacitet att avancera till en ny nivå. Den nya strategin, ASCENT25, avser att accelerera företagets tillväxt, värdeskapande och inno
USD TENDER OPERATION ANNOUNCEMENT2.3.2021 16:20:00 CET | Press release
Bid date, 2021-03-04Bid Date2021-03-04Bid times14.00-14.30 (CET/CEST) on the Bid dateOfferent AmountUSD 10 billionMaximum Permitted Volume of BidsUSD 4 billion from an individual institutionSettlement Date2021-03-08Minimum Permitted Bid Volume100 USD million per bidMaximum Allocation40 per cent of the Offerend amountAllocation timeNot later than 15.00 (CET/CEST) on the Bid dateMaturity Date2021-05-28Maximum Number of Bids10 per individual institutionLowest Interest Supplement0.25 percentage pointsConfirmation of bids to email@example.com Stockholm, 2021-03-02 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
RAPALA VMC CORPORATION - FINANCIAL STATEMENTS AND CORPORATE GOVERNANCE STATEMENT 2020 PUBLISHED2.3.2021 16:00:00 CET | Press release
Rapala VMC Corporation Stock Exchange Release March 2, 2021 at 5:00 p.m. RAPALA VMC CORPORATION - FINANCIAL STATEMENTS AND CORPORATE GOVERNANCE STATEMENT 2020 PUBLISHED Rapala VMC Corporation’s Financial Statements and Corporate Governance Statement 2020 have been published as attachments to this stock exchange release. These statements and other investor information as well as report on corporate responsibility and remuneration report are available on the Group’s corporate website at www.rapalavmc.com in English and Finnish. For the first time, Rapala VMC Corporation publishes the Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements. In line with the ESEF requirements, the primary statements have been labelled with XBRL tags. These XBRL tags have not been subject to audit. RAPALA VMC CORPORATION Nicolas Warchalowski President and Chief Executive Officer For further information: Olli Aho, Investor Relations, tel. +358 9 7562 540 Distri
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting2.3.2021 15:26:23 CET | Press release
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flow Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as well as all other members who stood for re-election Shareholders approve all other proposals of the Board of Directors, including the 2020 Compensation Report in an advisory vote, as well as the future Board and Executive Committee compensation in separate binding votes Basel, March 2, 2021 — Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the Group’s Annual General Meeting (AGM). In accordance with the Swiss COVID-19 Ordinance 3, the 2021 AGM was held without shareholders being physically present. Accordingly, shareholders exercised their shareholder rights via the Independent Proxy and could follow the AGM via a live webcast. In addition, shareholders had the opportunity to s